. Author manuscript; available in PMC: 2019 Mar 1.

Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2017 Dec 28;57(3):166–174. doi: 10.1016/j.jaac.2017.12.009

Table 1.

Participant Demographics

	COS	Sibling (SIB)	Control (C)	P
N	32	30	39
Age (mean ± SE)	21.3 ± 1.1	19.4 ± 0.8	20.0 ± 0.7	.3
Sex (F:M)	16:16	13:17	18:21	.87
Parental SES³³	56.9 ± 28.3	49.9 ± 21.9	41.1 ± 17.5
DVARS (mean ± SE BOLD%)	0.87 ± 0.07	0.64 ± 0.03	0.77 ± 0.13	.27
Illness duration (years, mean [SE])	11.3 ± 1.1
Medication (chlorpromazine equivalents, mg, mean [SE])	943 ± 113

Note. DVARS represents a measurement of degree of motion and other artefactual changes in image intensity. Illness duration was the time between initial reporting of symptoms and functional magnetic resonance imaging (fMRI) date. All patients were taking antipsychotics at the time of scanning, typically clozapine. Medication doses are converted chlorpromazine equivalents.⁴⁵ Fisher’s exact tests were used for sex comparison, F tests for others. COS = childhood-onset schizophrenia; SE = standard error of the mean; SES = socioeconomic status. All p > .16